Table III.
Impact of using the pharmacogenomics clinical decision support (PGx-CDS) system on quantity of drug prescribed (in mg) among fourty-five encounters with the third through fifth clinical case scenarios for which physicians completed both pre- and post-PGx surveys.
| Prescribing task for each clinical case scenario | Standardized guidelines (yes/no) | Pre PGx-CDS system dosing (Mean +/− SD) | Post PGx-CDS system dosing (Mean +/− SD) | Z-value |
|---|---|---|---|---|
| Cardiology medications | ||||
| Warfarin (n=7) | Yes (Ref 25) | 5 ± 1.4 | 4.1 ± 1.2 | 1.41 |
| Clopidogrel (n=5) | No# | 75 ± 0 | 45 ± 67.1 | 1.00 |
| Propafenone (n=6) | No | 228 ± 197 | 100 ± 77.5 | 1.71 |
| Oncology medications | ||||
| Irinotecan (n=8) | No | 59.4 ± 4.2 | 40.6 ± 25.7 | 1.98* |
| Capecitabine (n=12) | No# | 1050 ± 127.9 | 237.6 ± 444.2 | 3.05** |
| Mercaptopurine/Thioguanine (n=7) | Yes (Ref 26, 27) | 59.7 ± 22.78 | 24.1 ± 26.2 | 2.17* |